FDA Approves SKYRIZI — AbbVie Inc.

AbbVie announced the FDA approval of risankizumab-RZAA (Skyrizi) for intravenous use, a formulation that may broaden the biologic’s market presence alongside its current subcutaneous standing. This regulatory expansion is expected to strengthen AbbVie’s position in the psoriasis sector by addressing physician and patient preferences for different administration routes.